Year: 2023

– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024 – Zeno interim clinical data continue to show robust efficacy in NRG1+ NSCLC and PDAC: Sufficient clinical data expected in 1H24 to support potential BLA submissions – Based on the Company’s current operating plan and recent oversubscribed public offering raising approximately $172M gross proceeds, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial...

Continued Revenue Growth in Commercial Aerospace and Data Analytical Solutions Markets Further Reductions in Quarterly Selling, General and Administrative expenses Provides Update on Project Phoenix and Preliminary Anticipated Impact on 2024 Outlook PRINCETON JUNCTION, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) — MISTRAS Group, Inc. (MG: NYSE), a leading “one source” multinational provider of integrated technology-enabled asset protection solutions, reported financial results for its third quarter and nine months ended September 30, 2023. Highlights of the Third Quarter 2023*Revenue of $179.4 million, a 0.5% increase Gross profit of $54.4 million, with gross profit margin of 30.3%, a 20 basis points increase Non-cash goodwill impairment charge of $13.8 million in International segment triggered by macroeconomic factors...

On Track for Topline Results from SEQUOIA-HCM,a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM,in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Initiated Enrollment in ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2023. Net loss for the third quarter was $129.4 million, or $1.35 per share, compared to net loss for the third quarter of 2022 of $142.3 million, or $1.52 per share. Cash, cash equivalents and investments totaled $554.7 million on September 30, 2023. “During...

Kratos Thanatos Tactical UAV in Flight – Conceptual RenditionKratos Thanatos Tactical UAV in Flight – Conceptual Rendition        Third Quarter 2023 Revenues of $274.6 Million Reflect 20.1 Percent Organic Growth Over Third Quarter 2022 Revenues of $228.6 Million Third Quarter 2023 Revenues Reflect 22.0 Percent Organic Revenue Growth in Kratos Government Solutions Segment and 13.4 Percent Organic Revenue Growth in Kratos Unmanned Systems Segment Third Quarter 2023 Consolidated Book to Bill Ratio of 1.0 to 1 and Last Twelve Months Ended October 1, 2023 Consolidated Book to Bill Ratio of 1.1 to 1 SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology Company in the Defense, National Security and Global Markets, today reported its third quarter 2023 financial...

TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurance provider, today announced financial results for the third quarter of 2023. David Clare, President and CEO of Trisura, stated, “Trisura reported strong performance in the quarter with Operating net income of $31.7 million, or $0.67 per share, achieved through measured growth, underwriting profitability and enhanced investment income. Quarterly Net income of $14.8 million, or $0.31 per share, was impacted by the run-off of a US program and unrealized losses in the investment portfolio, partially offset by one-time benefits in the primary lines business. Maturation of our business and continued expansion with distribution partners drove increased market share and resulted in insurance revenue growth...